Literature DB >> 7479396

Stimulation of human prostate cancer cell lines by factors present in human osteoblast-like cells but not in bone marrow.

S H Lang1, W R Miller, F K Habib.   

Abstract

Secondary deposits of prostate tumours are frequently found in the skeleton where they produce osteoblastic lesions. In this study both osteoblast-like cells and bone marrow from the proximal femur have been cultured to determine whether or not they can release factors which could support the growth of secondary prostate tumours. Media conditioned by both osteoblast-like cells (OBCM) and bone marrow were examined for their potential to stimulate prostate carcinoma cell lines. Whilst the results obtained demonstrated that OBCM could enhance the growth of both the hormone sensitive (LNCaP) and hormone unresponsive (PC-3 and DU-145) prostate carcinoma cell lines, no proliferative effect could be shown on cell lines derived from cancers of the breast, bladder, and liver. Significantly, media conditioned by either bone marrow or human skin fibroblasts also had no effect on the growth of prostate carcinoma cell lines. This study supports the possibility that the proliferation of prostate cancer cells at secondary skeletal sites, in vivo, may be due to osteoblast derived factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7479396     DOI: 10.1002/pros.2990270508

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

1.  Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals.

Authors:  Hikaru Nishimori; Shogo Ehata; Hiroshi I Suzuki; Yoko Katsuno; Kohei Miyazono
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

2.  Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells.

Authors:  Leyre Brizuela; Claire Martin; Pauline Jeannot; Isabelle Ader; Cécile Gstalder; Guillaume Andrieu; Magalie Bocquet; Jean-Michel Laffosse; Anne Gomez-Brouchet; Bernard Malavaud; Roger A Sabbadini; Olivier Cuvillier
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

3.  Paracrine factors produced by bone marrow stromal cells induce apoptosis and neuroendocrine differentiation in prostate cancer cells.

Authors:  Chu Zhang; Mehrnoosh Soori; Fayth L Miles; Robert A Sikes; Daniel D Carson; Leland W K Chung; Mary C Farach-Carson
Journal:  Prostate       Date:  2011-02-01       Impact factor: 4.104

4.  Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression.

Authors:  Gang Wang; Simon Haile; Barbara Comuzzi; Amy H Tien; Jun Wang; Theresa M K Yong; Anca E Jelescu-Bodos; Natalie Blaszczyk; Robert L Vessella; Bassam A Masri; Marianne D Sadar
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

5.  Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.

Authors:  Jeffrey A Nemeth; Michael L Cher; Zhao Zhou; Chadwick Mullins; Sunita Bhagat; Mohit Trikha
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

6.  The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development.

Authors:  Paul G Corn
Journal:  Cancer Manag Res       Date:  2012-07-25       Impact factor: 3.989

7.  Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts.

Authors:  A Shiirevnyamba; T Takahashi; H Shan; H Ogawa; S Yano; H Kanayama; K Izumi; H Uehara
Journal:  Br J Cancer       Date:  2011-01-04       Impact factor: 7.640

Review 8.  Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis.

Authors:  Daniel E Hagaman; Jossana A Damasco; Joy Vanessa D Perez; Raniv D Rojo; Marites P Melancon
Journal:  Molecules       Date:  2021-01-13       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.